Clinical Characteristics of CML Patients and Results of In Vitro Studies
| Case . | Sex/Age . | Phase . | % CD34+ Cells Bearing CD95 . | Effect of IFN-α 1,000 U + Fas Triggering . | Hematologic Response to IFN-α . | % Ph+ Mitoses at 12 mo-153 . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| % of Apoptotic Cells-151 . | CFU-C/103CD34+ Plated . | p210-152 . | ||||||||
| Untreated . | Treated . | Untreated . | Treated . | % of Untreated . | ||||||
| 1-150 | M/35 | CP | 42 | 5.6 | 20.0 | 78.5 | 16 | 30 | Optimal | 60 |
| 2-150 | F/28 | CP | 25 | − | + | 137 | 25 | 50 | Optimal | 16 |
| 3 | F/53 | CP | 8.3 | 7.3 | 18.5 | 95.5 | 27.5 | 25 | Optimal | 20 |
| 4 | F/26 | CP | 9.5 | − | + | ND | ND | 40 | Optimal | 33 |
| 5-150 | F/40 | CP | 49 | − | + | 86.5 | 17.5 | 35 | Optimal | 61 |
| 6 | M/59 | CP | 3.2 | 6.6 | 21.0 | 122.5 | 19 | 25 | Optimal | 42 |
| 7 | M/33 | CP | 52 | 6.5 | 25.0 | 132 | 17.5 | 10 | Optimal | 75 |
| 8 | M/48 | CP | 13.5 | 9.0 | 16.5 | 87 | 68 | 90 | Optimal | 16 |
| X ± SD | 40 ± 12 | 25.3 ± 19 | 7.0 ± 1 | 20.2 ± 3 | 105.5 ± 24 | 27.1 ± 18 | 38.1 ± 24 | |||
| 9 | M/40 | CP | 15.2 | 9.0 | 13.5 | 102.5 | 88 | 95 | Poor | 80 |
| 10 | F/40 | CP | 17.8 | 8.0 | 11.5 | 170 | 158 | 100 | Poor | 100 |
| 11 | M/63 | CP | 4.5 | 9.0 | 10.5 | 65 | 62 | 100 | Poor | 90 |
| X ± SD | 47.6 ± 13 | 12.5 ± 7 | 8.6 ± 0.6 | 11.8 ± 1 | 112.5 ± 31 | 102.6 ± 29 | 98.3 ± 1.6 | |||
| 12 | M/58 | BC | 1.1 | 9.5 | 12.5 | 77 | 65 | 100 | NA | NA |
| Case . | Sex/Age . | Phase . | % CD34+ Cells Bearing CD95 . | Effect of IFN-α 1,000 U + Fas Triggering . | Hematologic Response to IFN-α . | % Ph+ Mitoses at 12 mo-153 . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| % of Apoptotic Cells-151 . | CFU-C/103CD34+ Plated . | p210-152 . | ||||||||
| Untreated . | Treated . | Untreated . | Treated . | % of Untreated . | ||||||
| 1-150 | M/35 | CP | 42 | 5.6 | 20.0 | 78.5 | 16 | 30 | Optimal | 60 |
| 2-150 | F/28 | CP | 25 | − | + | 137 | 25 | 50 | Optimal | 16 |
| 3 | F/53 | CP | 8.3 | 7.3 | 18.5 | 95.5 | 27.5 | 25 | Optimal | 20 |
| 4 | F/26 | CP | 9.5 | − | + | ND | ND | 40 | Optimal | 33 |
| 5-150 | F/40 | CP | 49 | − | + | 86.5 | 17.5 | 35 | Optimal | 61 |
| 6 | M/59 | CP | 3.2 | 6.6 | 21.0 | 122.5 | 19 | 25 | Optimal | 42 |
| 7 | M/33 | CP | 52 | 6.5 | 25.0 | 132 | 17.5 | 10 | Optimal | 75 |
| 8 | M/48 | CP | 13.5 | 9.0 | 16.5 | 87 | 68 | 90 | Optimal | 16 |
| X ± SD | 40 ± 12 | 25.3 ± 19 | 7.0 ± 1 | 20.2 ± 3 | 105.5 ± 24 | 27.1 ± 18 | 38.1 ± 24 | |||
| 9 | M/40 | CP | 15.2 | 9.0 | 13.5 | 102.5 | 88 | 95 | Poor | 80 |
| 10 | F/40 | CP | 17.8 | 8.0 | 11.5 | 170 | 158 | 100 | Poor | 100 |
| 11 | M/63 | CP | 4.5 | 9.0 | 10.5 | 65 | 62 | 100 | Poor | 90 |
| X ± SD | 47.6 ± 13 | 12.5 ± 7 | 8.6 ± 0.6 | 11.8 ± 1 | 112.5 ± 31 | 102.6 ± 29 | 98.3 ± 1.6 | |||
| 12 | M/58 | BC | 1.1 | 9.5 | 12.5 | 77 | 65 | 100 | NA | NA |
Abbreviations: CP, chronic phase; BC, blastic crisis; ND, not done; NA, not applicable.
Patients studied while under IFN-α treatment.
Numerical values: detected by Tdt assay; ± detected qualitatively by DNA laddering in agarose gel.
Detected by densitometric scanning of Western blotting films.
At diagnosis, all patients showed 100% Ph+ mitoses.